ANI Pharmaceuticals Valuation
| ANIP Stock | USD 64.26 0.09 0.14% |
At this time, the firm appears to be undervalued. ANI Pharmaceuticals shows a prevailing Real Value of $75.67 per share. The current price of the firm is $64.26. Our model approximates the value of ANI Pharmaceuticals from reviewing the firm fundamentals such as Operating Margin of 0.01 %, return on equity of -0.0418, and Profit Margin of (0.03) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ANI Pharmaceuticals' valuation include:
Price Book 3.4972 | Enterprise Value | Enterprise Value Ebitda 30.2517 | Price Sales 2.2794 | Forward PE 10.4493 |
Undervalued
Today
Please note that ANI Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of ANI Pharmaceuticals is based on 3 months time horizon. Increasing ANI Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ANI Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 64.26, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 64.26 | Real 75.67 | Target 78.67 | Hype 63.9 | Naive 65.55 |
The intrinsic value of ANI Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ANI Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ANI Pharmaceuticals helps investors to forecast how ANI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ANI Pharmaceuticals more accurately as focusing exclusively on ANI Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ANI Pharmaceuticals' intrinsic value based on its ongoing forecasts of ANI Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ANI Pharmaceuticals' closest peers.
ANI Pharmaceuticals Cash |
|
ANI Valuation Trend
ANI Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of ANI Pharmaceuticals' financial worth over time. Using both ANI Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
ANI Pharmaceuticals Total Value Analysis
ANI Pharmaceuticals is presently forecasted to have valuation of 1.91 B with market capitalization of 1.4 B, debt of 314.98 M, and cash on hands of 63.38 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ANI Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.91 B | 1.4 B | 314.98 M | 63.38 M |
ANI Pharmaceuticals Investor Information
About 97.0% of the company shares are held by institutions such as insurance companies. The book value of ANI Pharmaceuticals was presently reported as 20.54. The company has Price/Earnings To Growth (PEG) ratio of 1.06. ANI Pharmaceuticals recorded a loss per share of 1.04. The entity had not issued any dividends in recent years. The firm had 1:6 split on the 18th of July 2013. Based on the key indicators related to ANI Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, ANI Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.ANI Pharmaceuticals Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of ANI connotes not a very effective usage of assets in March.ANI Pharmaceuticals Ownership Allocation
ANI Pharmaceuticals holds a total of 21.76 Million outstanding shares. The majority of ANI Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ANI Pharmaceuticals to benefit from reduced commissions. Thus, institutional investors are subject to a different set of regulations than regular investors in ANI Pharmaceuticals. Please pay attention to any change in the institutional holdings of ANI Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that nearly one million eight hundred seventy-eight thousand one hundred twelve invesors are currently shorting ANI Pharmaceuticals expressing very little confidence in its future performance.ANI Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 614.38 M. Net Loss for the year was (18.52 M) with profit before overhead, payroll, taxes, and interest of 364.17 M.About ANI Pharmaceuticals Valuation
The stock valuation mechanism determines ANI Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of ANI Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ANI Pharmaceuticals. We calculate exposure to ANI Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ANI Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 614.4 M | 645.1 M | |
| Pretax Profit Margin | (0.04) | (0.04) | |
| Net Loss | (0.03) | (0.03) | |
| Gross Profit Margin | 0.56 | 0.34 |
ANI Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as ANI Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 19.3 M | |
| Quarterly Earnings Growth Y O Y | 13.824 | |
| Forward Price Earnings | 10.4493 |
ANI Pharmaceuticals Current Valuation Indicators
ANI Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ANI Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ANI Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ANI Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ANI Pharmaceuticals' worth.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.